Scientific reports, 2020-07, Vol.10 (1), p.12546-12546, Article 12546
2020
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Comparative efficacy of antitumor necrosis factor agents and tacrolimus in naïve steroid-refractory ulcerative colitis patients
- Ist Teil von
- Scientific reports, 2020-07, Vol.10 (1), p.12546-12546, Article 12546
- Ort / Verlag
- England: Nature Publishing Group
- Erscheinungsjahr
- 2020
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- While retrospective studies have compared the efficacy of anti-tumour necrosis factor (TNF) agents and tacrolimus (TAC) in ulcerative colitis (UC), information regarding first-time use of these agents is limited. The aim of our study was to investigate the short- and long-term efficacy of anti-TNF agents [adalimumab (ADA) and infliximab (IFX)] and TAC in anti-TNF agent- and TAC-naïve steroid-refractory UC patients. We evaluated 150 steroid-refractory UC patients receiving anti-TNF agents (IFX: n = 30, ADA: n = 41) or TAC (n = 79) at eight institutions in Japan. Clinical response rates at 8 weeks were 73.2% and 75.9% while remission rates were 30.1% and 25.3% in the anti-TNF and TAC groups, respectively. Logistic regression analysis showed the male sex and higher C-reactive protein to be independent factors for response to anti-TNF agents and TAC, respectively. Use of TAC was an independent factor for relapse. No differences in response to the treatment or relapse were observed between IFX and ADA. In conclusion, TAC and anti-TNF agents promoted similar short-term effects, but anti-TNF agents ensured better long-term outcomes at first-time treatment of steroid-refractory UC patients.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 2045-2322eISSN: 2045-2322DOI: 10.1038/s41598-020-68828-zTitel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7385627
- Format
- –
- Schlagworte
- Adalimumab - therapeutic use, Adult, Antitumor activity, C-reactive protein, C-Reactive Protein - metabolism, Colitis, Ulcerative - drug therapy, Female, Humans, Inflammatory bowel disease, Infliximab, Infliximab - therapeutic use, Logistic Models, Male, Middle Aged, Monoclonal antibodies, Necrosis, Patients, Proportional Hazards Models, Remission, Steroids - therapeutic use, Tacrolimus, Tacrolimus - therapeutic use, Treatment Outcome, Tumor Necrosis Factor-alpha - antagonists & inhibitors, Tumor Necrosis Factor-alpha - metabolism, Tumor necrosis factor-TNF, Tumor necrosis factor-α, Tumors, Ulcerative colitis